Trials / Completed
CompletedNCT03663569
A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler
Changes in Clinical Control of COPD Patients Measured by the Clinical COPD Questionnaire During Therapy With Spiolto®Respimat® in Routine Clinical Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,819 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
Open-label observational study which includes COPD patients that are receiving treatment with Spiolto® Respimat® for approximately 6 weeks, which is the average time between two medical consultations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Spiolto® Respimat® | Drug |
Timeline
- Start date
- 2018-08-15
- Primary completion
- 2019-10-04
- Completion
- 2019-10-04
- First posted
- 2018-09-10
- Last updated
- 2025-01-07
- Results posted
- 2020-10-22
Locations
388 sites across 11 countries: Bulgaria, Czechia, Hungary, Israel, Lithuania, Poland, Romania, Russia, Slovenia, Switzerland, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03663569. Inclusion in this directory is not an endorsement.